Resonic and Durysta — Definite-lived intangible assets impairment charges
Products & Services · Definite-lived intangible assets impairment chargesAnalysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ3 2025
Last reportedQ3 2025
How to read this metric
An increase indicates a deterioration in the commercial outlook or competitive positioning of the specific product line, while a decrease suggests stable or improving asset performance.
Detailed definition
This metric represents the non-cash expense recognized when the carrying value of definite-lived intangible assets assoc...
Peer comparison
Peers in the pharmaceutical industry frequently report similar impairment charges when specific drug candidates or acquired product lines fail to meet clinical or commercial milestones.
Metric ID:
abbv_segment_resonic_and_durysta_definite_lived_intangible_assets_impairment_chargesHistorical Data
1 periods
| Q3 '25 | |
|---|---|
| Value | $847.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's resonic and durysta — definite-lived intangible assets impairment charges?
- AbbVie (ABBV) reported resonic and durysta — definite-lived intangible assets impairment charges of $847.00M in Q3 2025.
- What does resonic and durysta — definite-lived intangible assets impairment charges mean?
- The amount of value written off from specific product-related intangible assets because they are no longer expected to generate as much profit as originally projected.